(Q37928299)

25 August 2017

1 reference

title

Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia (English)

1 reference

25 August 2017

0 references

1 reference

1 reference

1 reference

Ginah Nightingale

1

1 reference

25 August 2017

language of work or name

English

0 references

publication date

6 September 2011

1 reference

Annals of Pharmacotherapy

25 August 2017

published in

1 reference

25 August 2017

volume

45

1 reference

25 August 2017

issue

10

1 reference

25 August 2017

page(s)

1248-1255

1 reference

25 August 2017

cites work

Cancer statistics, 2010

1 reference

Current approach to diagnosis and management of chronic lymphocytic leukemia

21 January 2018

1 reference

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

21 January 2018

1 reference

Plasma quantitation of JAK2 mutation is not suitable as a clinical test: an artifact of storage

21 January 2018

1 reference

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy

21 January 2018

1 reference

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

21 January 2018

1 reference

Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma

21 January 2018

1 reference

Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody

21 January 2018

1 reference

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

21 January 2018

1 reference

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

21 January 2018

1 reference

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

21 January 2018

1 reference

Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1P780

1 reference

25 August 2017

1 reference